Premium
Enhancement of humoral immune responses to a human cytomegalovirus DNA vaccine: Adjuvant effects of aluminum phosphate and CpG oligodeoxynucleotides
Author(s) -
Temperton Nigel J.,
Quenelle Debra C.,
Lawson Keirissa M.,
Zuckerman Jane N.,
Kern Earl R.,
Griffiths Paul D.,
Emery Vincent C.
Publication year - 2003
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.10357
Subject(s) - adjuvant , cpg oligodeoxynucleotide , virology , antibody , immunization , human cytomegalovirus , neutralizing antibody , cpg site , immune system , antibody titer , titer , immunology , biology , virus , biochemistry , gene expression , dna methylation , gene
A human cytomegalovirus (HCMV) glycoprotein B (gpUL55) DNA vaccine has been evaluated in BALB/c mice. Intramuscular immunization of these mice with pRc/CMV2‐gB resulted in the generation of high levels of gpUL55‐specific antibody (geometric mean titer [GMT] 1:8900) and neutralizing antibody (GMT 1:74) after 2 booster doses given 5 and 10 weeks after primary inoculation. Emulsifying the construct with the aluminum phosphate gel adjuvant Adju‐Phos before immunization enhanced gpUL55‐specific antibody responses (GMT 1:17800, P = 0.04). Co‐immunization with CpG oligodeoxynucleotides was shown to enhance levels of neutralizing antibodies generated by immunization of mice with a pRc/CMV2‐gB/Adju‐Phos emulsion ( P = 0.04). The results provide a rationale for evaluating combinations of other HCMV proteins for incorporation into a multi‐target DNA vaccine, and for the optimization of adjuvant usage, to elicit enhanced levels of neutralizing antibodies. J. Med. Virol. 70:86–90, 2003. © 2003 Wiley‐Liss, Inc.